vTv Therapeutics Stock (NASDAQ:VTVT), Trade Ideas

vTv Therapeutics

vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics Inc

vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) reported quarterly losses of $(1.67) per share. This is a 26.75 percent increase over losses of $(2.28) per share from the same period last year.

Earnings

News

VTVT

vTv Therapeutics Q4 EPS $(1.67) Up From $(2.28) YoY

<h3>Gainers</h3>
<ul>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) stock increased by 62.4% to $1.4 during Tuesday's after-market session. The company's market cap stands at $30.6 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock moved upwards by 13.17% to $15.55. The company's market cap stands at $32.4 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) stock increased by 9.09% to $2.16. The company's market cap stands at $391.3 million. The company's, Q4 earnings came out today. </li>
<li>Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) stock increased by 7.32% to $6.01. The company's market cap stands at $391.4 million. The company's, Q4 earnings came out today. </li>
<li>YS Biopharma Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YS#NASDAQ">YS</a>) stock rose 6.36% to $0.65. The market value of their outstanding shares is at $122.1 million. </li>
<li>Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) shares increased by 6.1% to $4.17. The company's market cap stands at $245.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares decreased by 22.2% to $0.14 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) stock decreased by 12.56% to $8.08. The company's market cap stands at $440.9 million. As per the press release, Q4 earnings came out today. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) shares declined by 10.39% to $1.64. The company's market cap stands at $209.0 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares decreased by 8.8% to $0.83. The market value of their outstanding shares is at $45.2 million. The company's, Q4 earnings came out yesterday. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) stock fell 8.42% to $10.89. The company's market cap stands at $40.7 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares fell 8.01% to $8.5. The market value of their outstanding shares is at $166.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALDX

CARA

CERS

CMAX

CMPX

Envoy Medical, Inc. - Class A Common Stock

COCH

HSCS

MRNS

NKGN

SOPH

12 Health Care Stocks Moving In Tuesday's After-Market Session

Biotech

General

vTv Therapeutics Announces FDA Submission For Phase 3 Study Of Cadisegliatin In Patients With Type 1 Diabetes

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday.
The Dow traded down 0.27% to 38,867.91 while the NASDAQ fell 0.50% to 15,954.75. The S&amp;P 500 also fell, dropping, 0.18% to 5,068.92.
Check This Out: <a href="https://www.benzinga.com/news/24/02/37361652/robinhood-shake-shack-and-2-other-stocks-insiders-are-selling"> Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Real estate shares rose by 1.4% on Wednesday.
In trading on Wednesday, communication services shares fell by 0.8%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
ADT Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/adt#NYSE">ADT</a>) reported better-than-expected earnings for its fourth quarter on Wednesday.
ADT posted fourth-quarter fiscal 2023 sales decline of 7.2% year-on-year to $1.22 billion, missing the consensus of $1.44 billion. Adjusted EPS was 25 cents, beating the consensus of 4 cents.
ADT expects CSB segment revenue of 4.8 billion-$5.0 billion. The company expects adjusted EPS of $0.60 &ndash; $0.70, against consensus of $0.50.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Vivani Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vani#NASDAQ">VANI</a>) shares shot up 274% to $3.78 after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139.
Shares of Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) got a boost, surging 159% to $2.1917. Adial Pharmaceuticals secured new US patent covering lead product for alcohol use disorder.
vTv Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtvt#NASDAQ">VTVT</a>) shares were also up, gaining 117% to $18.05 after the company announced a $51 million private placement from healthcare-focused institutional investors and the JDRF T1D Fund.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Oragenics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogen#NYSE">OGEN</a>) shares dropped 42% to $1.42. Oragenics priced its public offering 1.4 million common shares at $1.50 per share for gross proceeds of $2.1 million.
Shares of Integral Ad Science Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ias#NASDAQ">IAS</a>) were down 42% to $9.92 after the company reported fourth-quarter financial results.
Inogen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ingn#NASDAQ">INGN</a>) was down, falling 35% to $6.08 following weak quarterly results.
Also Check This Out:<a href="https://www.benzinga.com/news/24/02/37334066/top-3-energy-stocks-that-could-sink-your-portfolio-in-q1"> Top 3 Energy Stocks That Could Sink Your Portfolio In Q1 </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.3% to $78.65 while gold traded down 0.2% at $2,040.40.
Silver traded fell 0.5% to $22.645 on Wednesday while copper fell 0.3% to $3.8390.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly lower today. The eurozone&rsquo;s STOXX 600 fell 0.35%, London&rsquo;s FTSE 100 fell 0.76% while Spain&rsquo;s IBEX 35 Index fell 0.45% The German DAX gained 0.25% French CAC 40 rose 0.08% while Italy&rsquo;s FTSE MIB Index declined 0.27%.
The services confidence indicator in the Eurozone fell to 6 in February, the lowest in three months, while economic sentiment indicator fell to 95.4 in February. The consumer confidence indicator in the Eurozone increased by 0.6 points to a reading of -15.5 in February.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed lower on Wednesday, with Japan&rsquo;s Nikkei 225 falling 0.08%, Hong Kong&rsquo;s Hang Seng Index dipping 1.51%, China&rsquo;s Shanghai Composite Index tumbling 1.91% and India&rsquo;s S&amp;P BSE Sensex falling 1.08%.
Hong Kong&rsquo;s GDP increased by 4.3% year-over-year in the fourth quarter, up from a 4.1% increase in the prior period. The index of leading economic indicators in Japan was revised higher to 110.2 in December versus preliminary reading of 110, while index of coincident economic indicators was revised lower to 115.9 in December versus a flash reading of 116.2.
&nbsp;
<h3>Economics</h3>
&nbsp;
U.S. mortgage applications fell by 5.6% on the week ending Feb. 23.
The U.S. economy grew an annualized 3.2% in the fourth quarter, versus a 4.9% rate in the previous quarter.
The U.S. trade deficit in goods rose to $90.20 billion in January versus a revised $87.89 billion in the prior month.
U.S. wholesale inventories declined by 0.1% month-over-month in January following a 0.4% increase a month ago.
U.S. crude oil inventories increased by 4.199 million barrels in the week ending Feb. 23, versus market estimates of a 2.743 million gain, the EIA said.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37356403/cramer-says-this-ai-stock-is-just-an-nvidia-play-prefers-this-stock-over-anheuser-busch"> Cramer Says This AI Stock Is Just An Nvidia Play, Prefers This Stock Over Anheuser-Busch </a>

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

ADIL

INGN

OGEN

VANI

S&P 500 Edges Lower; ADT Posts Upbeat Earnings

Shares of Bumble Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmbl#NASDAQ">BMBL</a>) fell sharply during Wednesday&rsquo;s session <a href="https://www.benzinga.com/news/earnings/24/02/37349026/bumble-reports-q4-results-eps-miss-revenue-miss-workforce-reductions">following weak quarterly results</a>.
Bumble reported quarterly losses of 19 cents per share which missed the analyst consensus estimate of 12 cents per share. The company reported quarterly sales of $273.64 million which missed the analyst consensus estimate of $275.29 million.
Bumble shares dipped 11.6% to $11.65 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Vivani Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vani#NASDAQ">VANI</a>) shares jumped 289% to $3.93 after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) climbed 190% to $2.4598. Adial Pharmaceuticals secured new US patent covering lead product for alcohol use disorder.</li>
<li>vTv Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtvt#NASDAQ">VTVT</a>) gained 112% to $17.65 after the company announced a $51 million private placement from healthcare-focused institutional investors and the JDRF T1D Fund.</li>
<li>Bit Brother Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bets#NASDAQ">BETS</a>) shares rose 63.7% to $4.0750.</li>
<li>Beyond Meat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bynd#NASDAQ">BYND</a>) climbed 45% to $10.90 as the company reported stronger-than-expected sales for its fourth quarter.</li>
<li>Incannex Healthcare Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ixhl#NASDAQ">IXHL</a>) gained 43.6% to $6.06 after the company announced its Psi-GAD1 trial met its primary endpoint.</li>
<li>Bandwidth Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/band#NASDAQ">BAND</a>) surged 43.3% to $17.41 after the company reported better-than-expected fourth quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Imunon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imnn#NASDAQ">IMNN</a>) climbed 38% to $0.98.</li>
<li>Applied Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aplt#NASDAQ">APLT</a>) surged 36% to $7.59 after the company announced FDA acceptance and priority review of the NDA for govorestat for the treatment of Classic Galactosemia. The company also announced a $100 million private placement.</li>
<li>Movella Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mvla#NASDAQ">MVLA</a>) gained 33.5% to $0.33.</li>
<li>LifeStance Health Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lfst#NASDAQ">LFST</a>) gained 31.5% to $8.81 following strong quarterly sales.</li>
<li>AirNet Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ante#NASDAQ">ANTE</a>) rose 31.3% to $1.05. AirNet announced changes in senior management team.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psny#NASDAQ">PSNY</a>) rose 29.9% to $1.9350. Polestar secured $1 billion external funding.</li>
<li>Editas Medicine, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/edit#NASDAQ">EDIT</a>) gained 27.7% to $11.31 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>TG Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgtx#NASDAQ">TGTX</a>) jumped 27.2% to $17.69 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Qurate Retail, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qrtea#NASDAQ">QRTEA</a>) rose 22% to $1.71 after the company reported fourth-quarter financial results.</li>
<li>B&amp;G Foods, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bgs#NYSE">BGS</a>) gained 21.4% to $11.41 after the company reported better-than-expected fourth-quarter financial results and issued FY24 revenue guidance.</li>
<li>Flywire Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flyw#NASDAQ">FLYW</a>) gained 20% to $29.40 after the company reported better-than-expected fourth quarter financial results.</li>
<li>Flywire Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flyw#NASDAQ">FLYW</a>) climbed 17.6% to $28.84 after the company reported better-than-expected fourth quarter financial results.</li>
<li>The Vita Coco Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coco#NASDAQ">COCO</a>) surged 17.3% to $26.32 after the company reported better-than-expected fourth-quarter financial results and issued FY24 net sales guidance.</li>
<li>J-Long Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jl#NASDAQ">JL</a>) gained 17.2% to $18.90.</li>
<li>Revolve Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rvlv#NYSE">RVLV</a>) rose 16% to $20.28 as the company reported upbeat results for its fourth quarter on Tuesday.</li>
<li>Nauticus Robotics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kitt#NASDAQ">KITT</a>) gained 15.9% to $0.3549.</li>
<li>Life Time Group Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lth#NYSE">LTH</a>) gained 15.3% to $14.32 after the company reported better-than-expected fourth quarter financial results and issued first-quarter revenue guidance above estimates.</li>
<li>Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) shares jumped 15% to $6.96 in pre-market trading following fourth-quarter results.</li>
<li>Connexa Sports Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnxa#NASDAQ">CNXA</a>) shares jumped 14.3% to $0.27.</li>
<li>ACM Research, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acmr#NASDAQ">ACMR</a>) rose 13.6% to $24.75 in pre-market trading after the company reported better-than-expected fourth-quarter FY23 results.</li>
<li>Vipshop Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vips#NYSE">VIPS</a>) gained 12.4% to $19.49 after the company reported better-than-expected fourth quarter financial results.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) climbed 10.9% to $967.01.</li>
<li>Chart Industries, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gtls#NASDAQ">GTLS</a>) rose 10.5% to $145.33 after the company reported mixed fourth quarter financial results and issued FY24 adjusted EPS guidance above estimates.</li>
<li>Assured Guaranty Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ago#NYSE">AGO</a>) gained 9.8% to $94.11 following fourth quarter financial results.</li>
<li>eBay Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ebay#NASDAQ">EBAY</a>) rose 8.4% to $48.15 after the company reported better-than-expected fourth quarter financial results.</li>
<li>ADT Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/adt#NYSE">ADT</a>) climbed 7.2% to $7.00 following upbeat earnings.</li>
<li>Advance Auto Parts, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aap#NYSE">AAP</a>) gained 7.1% to $69.32 fourth quarter financial results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Oragenics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogen#NYSE">OGEN</a>) shares fell 43.3% to $1.39. Oragenics priced its public offering 1.4 million common shares at $1.50 per share for gross proceeds of $2.1 million.</li>
<li>Integral Ad Science Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ias#NASDAQ">IAS</a>) fell 40.2% to $1.39 after the company reported fourth-quarter financial results.</li>
<li>Charge Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crge#NASDAQ">CRGE</a>) fell 36.8% to $0.0379.</li>
<li>Palatin Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ptn#NYSE">PTN</a>) fell 34.8% to $2.5880 after the company reported results of PL9643 MELODY-1 pivotal Phase 3 clinical trial in patients with dry eye disease.</li>
<li>Inogen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ingn#NASDAQ">INGN</a>) dipped 31.2% to $6.43 following weak results.</li>
<li>Eventbrite, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eb#NYSE">EB</a>) fell 30.2% to $5.81 after the company reported mixed fourth-quarter financial results.</li>
<li>Solarmax Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smxt#NASDAQ">SMXT</a>) shares fell 27.5% to $5.81. SolarMax Technology announced pricing of initial public offering and listing on Nasdaq.</li>
<li>Novavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvax#NASDAQ">NVAX</a>) dipped 27% to $4.4000 after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter revenue guidance below estimates.</li>
<li>Lemonade, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lmnd#NYSE">LMND</a>) shares declined 26.1% to $16.04 after the company reported fourth-quarter financial results.</li>
<li>Vicarious Surgical Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rbot#NYSE">RBOT</a>) fell 24% to $0.4099 after jumping 57% on Tuesday.</li>
<li>Ocean Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocea#NASDAQ">OCEA</a>) dipped 21.9% to $1.53.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) fell 21.8% to $1.00.</li>
<li>3D Systems Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ddd#NYSE">DDD</a>) fell 21.6% to $4.10 following weak fourth-quarter financial results.</li>
<li>Nerdy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nrdy#NYSE">NRDY</a>) fell 21% to $2.4099 following fourth-quarter financial results.</li>
<li>Vertex Energy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vtnr#NYSE">VTNR</a>) shares dipped 20.7% to $1.3310 after posting a fourth-quarter loss.</li>
<li>Alignment Healthcare, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alhc#NASDAQ">ALHC</a>) fell 17.5% to $5.71 after the company reported worse-than-expected fourth-quarter GAAP EPS results.</li>
<li>Progyny, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pgny#NASDAQ">PGNY</a>) fell 17.2% to $33.79 after the company reported mixed fourth-quarter financial results.</li>
<li>The Boston Beer Company, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sam#NYSE">SAM</a>) dipped 17.1% to $306.80 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Payoneer Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/payo#NASDAQ">PAYO</a>) fell 15.6% to $4.69 after the company issued FY24 revenue guidance below estimates.</li>
<li>Concentrix Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnxc#NASDAQ">CNXC</a>) fell 15.3% to $70.25.</li>
<li>Urban Outfitters, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/urbn#NASDAQ">URBN</a>) shares declined 15% to $40.08 after the company reported fourth-quarter financial results.</li>
<li>Hyster-Yale Materials Handling, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hy#NYSE">HY</a>) fell 14.1% to $60.20 following fourth-quarter results.</li>
<li>The E.W. Scripps Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssp#NASDAQ">SSP</a>) fell 12.2% to $4.1050 after the company reported mixed fourth-quarter financial results.</li>
<li>Luminar Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lazr#NASDAQ">LAZR</a>) dipped 10% to $2.25 following downbeat quarterly results.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxrx#NASDAQ">RXRX</a>) shares fell 9.1% to $14.10 after the company reported mixed fourth-quarter financial results.</li>
<li>Baidu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bidu#NASDAQ">BIDU</a>) fell 7.1% to $104.42 after the company reported financial Q4 results.</li>
<li>Macy&#39;s, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/m#NYSE">M</a>) fell 4.8% to $18.99.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/37366156/snowflake-gears-up-for-q4-print-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-cal"> Snowflake Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call </a>

ACMR

ALHC

ANTE

APLT

BAND

BETS

BIDU

BMBL

BYND

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

CNXC

COCO

CRGE

EBAY

EDIT

FLYW

GTLS

IFBD

IMNN

IXHL

KITT

LAZR

LFST

LMND

MSTR

MVLA

NRDY

NVAX

OCEA

PAYO

PGNY

PSNY

QRTEA

RBOT

RVLV

RXRX

SMXT

TGTX

URBN

VIPS

VTNR

VTYX

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Wednesday,&nbsp;vTv Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares are soaring on a robust session volume of 2.7 million, compared to the average volume of 31.92 K as per the data from&nbsp;<a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
The company closed a private placement to healthcare-focused institutional investors, including a life sciences-focused institutional investor, Samsara BioCapital, and the JDRF T1D Fund, of 464,377 shares at $11.81 per share and pre-funded warrants for 3.85 million shares in lieu of vTv common stock in a private placement financing for total gross&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/g37361230/vtv-therapeutics-announces-51-million-private-placement-from-healthcare-focused-institutional-inve" rel="noreferrer noopener">proceeds of $51 million</a>.
Further, in conjunction with the PIPE, vTv has reduced the size of its Board of Directors from nine to seven members, three of whose members will be designated by the new investors, and includes Srinivas Akkaraju, MD, PhD, Founder and Managing General Partner at Samsara.&nbsp;
vTv will use the proceeds to fund the first Phase 3 study of its lead product candidate, cadisegliatin, which is expected to be initiated in mid-2024.
vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small-molecule drug candidates.&nbsp;
vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for type 1 diabetes.
Price Action: VTVT shares are up 103.8% at $17.32 on the last check Wednesday.
Photo: Darko Stojanovic from Pixabay

Equities

Health Care

Financing

Offerings

Why Is Diabetes Focused vTv Therapeutics Stock Trading Higher Today?

<h3>Gainers</h3>
<ul>
<li>Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) stock increased by 314.4% to $4.19 during Wednesday's regular session. The company's market cap stands at $213.5 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock moved upwards by 157.73% to $2.25. The market value of their outstanding shares is at $3.7 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares moved upwards by 105.88% to $17.5. The market value of their outstanding shares is at $35.6 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares increased by 40.27% to $0.71. The company's market cap stands at $6.6 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares rose 36.61% to $0.97. The company's market cap stands at $9.1 million. </li>
<li>G1 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTHX#NASDAQ">GTHX</a>) stock rose 35.2% to $3.25. The market value of their outstanding shares is at $168.2 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock declined by 42.9% to $1.4 during Wednesday's regular session. The company's market cap stands at $4.3 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock declined by 37.41% to $2.48. The market value of their outstanding shares is at $40.0 million. </li>
<li>Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) stock declined by 35.44% to $6.03. The market value of their outstanding shares is at $140.5 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock decreased by 27.41% to $4.37. The market value of their outstanding shares is at $519.1 million. As per the news, the Q4 earnings report came out today. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares fell 24.41% to $0.41. The market value of their outstanding shares is at $71.3 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock fell 23.47% to $1.5. The company's market cap stands at $51.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

GTHX

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 50 points on Wednesday.
The Dow traded down 0.19% to 38,899.92 while the NASDAQ fell 0.31% to 15,985.25. The S&amp;P 500 also fell, dropping, 0.11% to 5,072.67.
Check This Out: <a href="https://www.benzinga.com/news/24/02/37361652/robinhood-shake-shack-and-2-other-stocks-insiders-are-selling"> Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Real estate shares rose by 1.1% on Wednesday.
In trading on Wednesday, health care shares fell by 0.8%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
U.S. crude oil inventories increased by 4.199 million barrels in the week ending Feb. 23, versus market estimates of a 2.743 million gain, the EIA said.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Vivani Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vani#NASDAQ">VANI</a>) shares shot up 301% to $4.05 after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139.
Shares of Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) got a boost, surging 164% to $2.2350. Adial Pharmaceuticals secured new US patent covering lead product for alcohol use disorder.
vTv Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtvt#NASDAQ">VTVT</a>) shares were also up, gaining 136% to $19.61 after the company announced a $51 million private placement from healthcare-focused institutional investors and the JDRF T1D Fund.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Oragenics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogen#NYSE">OGEN</a>) shares dropped 43% to $1.40. Oragenics priced its public offering 1.4 million common shares at $1.50 per share for gross proceeds of $2.1 million.
Shares of Integral Ad Science Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ias#NASDAQ">IAS</a>) were down 41% to $10.15 after the company reported fourth-quarter financial results.
Inogen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ingn#NASDAQ">INGN</a>) was down, falling 35% to $6.12 following weak quarterly results.
Also Check This Out:<a href="https://www.benzinga.com/news/24/02/37334066/top-3-energy-stocks-that-could-sink-your-portfolio-in-q1"> Top 3 Energy Stocks That Could Sink Your Portfolio In Q1 </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.6% to $78.38 while gold traded down 0.1% at $2,043.80.
Silver traded fell 0.5% to $22.645 on Wednesday while copper fell 0.3% to $3.8390.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly lower today. The eurozone&rsquo;s STOXX 600 fell 0.35%, London&rsquo;s FTSE 100 fell 0.76% while Spain&rsquo;s IBEX 35 Index fell 0.45% The German DAX gained 0.25% French CAC 40 rose 0.08% while Italy&rsquo;s FTSE MIB Index declined 0.27%.
The services confidence indicator in the Eurozone fell to 6 in February, the lowest in three months, while economic sentiment indicator fell to 95.4 in February. The consumer confidence indicator in the Eurozone increased by 0.6 points to a reading of -15.5 in February.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed lower on Wednesday, with Japan&rsquo;s Nikkei 225 falling 0.08%, Hong Kong&rsquo;s Hang Seng Index dipping 1.51%, China&rsquo;s Shanghai Composite Index tumbling 1.91% and India&rsquo;s S&amp;P BSE Sensex falling 1.08%.
Hong Kong&rsquo;s GDP increased by 4.3% year-over-year in the fourth quarter, up from a 4.1% increase in the prior period. The index of leading economic indicators in Japan was revised higher to 110.2 in December versus preliminary reading of 110, while index of coincident economic indicators was revised lower to 115.9 in December versus a flash reading of 116.2.
&nbsp;
<h3>Economics</h3>
&nbsp;
U.S. mortgage applications fell by 5.6% on the week ending Feb. 23.
The U.S. economy grew an annualized 3.2% in the fourth quarter, versus a 4.9% rate in the previous quarter.
The U.S. trade deficit in goods rose to $90.20 billion in January versus a revised $87.89 billion in the prior month.
U.S. wholesale inventories declined by 0.1% month-over-month in January following a 0.4% increase a month ago.
U.S. crude oil inventories increased by 4.199 million barrels in the week ending Feb. 23, versus market estimates of a 2.743 million gain, the EIA said.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37356403/cramer-says-this-ai-stock-is-just-an-nvidia-play-prefers-this-stock-over-anheuser-busch"> Cramer Says This AI Stock Is Just An Nvidia Play, Prefers This Stock Over Anheuser-Busch </a>

Nasdaq Down 50 Points; US Crude Stocks Rise By 4.2M Barrels

vTv Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 117.4%

vTv Therapeutics Shares Resume Trading

vTv Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 143.3%

vTv Therapeutics Shares Resume Trade

vTv Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 105.7%

vTv Therapeutics Entered Into A Sales Agreement With Cowen And Company; Pursuant To Agreement Co May Offer And Sell Shares Of Class A Common Stock Having Aggregate Offering Price Of Up To $50.0M

WIIM

vTv Therapeutics shares are trading higher after the company announced a $51 million private placement from healthcare-focused institutional investors and the JDRF T1D Fund.

<h3>Gainers</h3>
<ul>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares increased by 104.2% to $17.36 during Wednesday's pre-market session. The market value of their outstanding shares is at $35.3 million. </li>
<li>Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) stock moved upwards by 67.32% to $1.69. The company's market cap stands at $86.2 million. </li>
<li>Genetic Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) shares moved upwards by 17.52% to $2.28. The market value of their outstanding shares is at $8.7 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock moved upwards by 14.28% to $0.8. The market value of their outstanding shares is at $15.8 million. </li>
<li>Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) shares moved upwards by 12.89% to $6.83. The company's market cap stands at $403.2 million. The company's, Q4 earnings came out yesterday. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares moved upwards by 12.08% to $0.8. The market value of their outstanding shares is at $7.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock fell 45.3% to $1.34 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.1 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock decreased by 34.26% to $2.61. The company's market cap stands at $42.1 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares declined by 21.43% to $0.42. The company's market cap stands at $74.2 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) shares declined by 15.73% to $1.34. The company's market cap stands at $90.9 million. </li>
<li>Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) shares fell 14.46% to $7.99. The market value of their outstanding shares is at $186.2 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock fell 13.63% to $5.2. The market value of their outstanding shares is at $617.7 million. As per the press release, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GENE

PROK

PRTG

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

vTv Therapeutics Announces $51M Private Placement From Healthcare-focused Institutional Investors Including Samsara BioCapital And The JDRF T1D Fund

Shares of Netflix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nflx#NASDAQ">NFLX</a>) shares rose sharply in today&rsquo;s pre-market trading as the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/01/36747282/netflix-q4-earnings-highlights-revenue-beat-13-12-million-net-paid-subscribers-q1-guidance-and-more">sales for its fourth quarter</a>.
Netflix reported fourth-quarter revenue of $8.83 billion, which was up 12.5% year-over-year. The total came in ahead of a Street consensus estimate of $8.72 billion. The company reported fourth-quarter earnings per share of $2.11, which missed a Street consensus estimate of $2.21.
The company, meanwhile, added 13.12 million net paid subscribers in the fourth quarter.
Netflix shares jumped 10.2% to $542.48 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Getaround, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/getr#NYSE">GETR</a>) gained 50.7% to $0.2771 in pre-market trading after the company announced a new debt facility with Mudrick Capital Management for up to $20 million.</li>
<li>Evaxion Biotech A/S (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evax#NASDAQ">EVAX</a>) gained 43.2% to $7.15 in pre-market trading after a 13G filing showed Merck &amp; Co reported an 11.4% stake in the company as of December 21, 2023.</li>
<li>VS MEDIA Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vsme#NASDAQ">VSME</a>) shares jumped 31.7% to $0.4318 in pre-market trading after gaining around 3% on Tuesday.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zcar#NASDAQ">ZCAR</a>) shares gained 18.1% to $3.98 in pre-market trading after gaining over 5% on Tuesday. Zoomcar recently appointed Adarsh Menon as President.</li>
<li>RedHill Biopharma Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdhl#NASDAQ">RDHL</a>) gained 17.8% to $1.05 in pre-market trading. Redhill Biopharma was granted U.S. Patent #11878011 for &quot;Method for Eradicating Helicobacter Pylori Infection in Patients Regardless of Body Mass Index.&quot;</li>
<li>Nyxoah S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nyxh#NASDAQ">NYXH</a>) surged 17.7% to $6.59 in pre-market trading after surging over 20% on Tuesday.</li>
<li>Greenidge Generation Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gree#NASDAQ">GREE</a>) shares climbed 15.7% to $4.10 in pre-market trading after falling more than 10% on Tuesday.</li>
<li>Cadrenal Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvkd#NASDAQ">CVKD</a>) shares gained 10.7% to $1.14 in pre-market trading.</li>
<li>Ensysce Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ensc#NASDAQ">ENSC</a>) shares gained 8.6% to $1.51 in pre-market trading. Ensysce Biosciences shares gained 22% on Tuesday after the company announced FDA Breakthrough Therapy Designation for PF614-MPAR.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Meta Materials Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mmat#NASDAQ">MMAT</a>) shares dipped 16.2% to $0.0560 in pre-market trading. Meta Materials announced a 1-for-100 reverse stock split to regain Nasdaq compliance.</li>
<li>BlackBerry Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bb#NYSE">BB</a>) shares fell 11% to $3.16 in pre-market trading after the company announced a proposed private offering of $160 million of convertible senior notes.</li>
<li>vTv Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtvt#NASDAQ">VTVT</a>) shares fell 9.4% to $8.48 in pre-market trading.</li>
<li>ETAO International Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etao#NASDAQ">ETAO</a>) fell 8.9% to $0.2010 after dipping over 20% on Tuesday.</li>
<li>Diversified Energy Company PLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dec#NYSE">DEC</a>) fell 8.9% to $11.74 in pre-market trading.</li>
<li>Sonoma Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snoa#NASDAQ">SNOA</a>) declined 8% to $0.1574 in pre-market trading. Sonoma pharmaceuticals announced the launch of Lumacyn Clarifying Mist direct to consumers for over-the-counter use in the US.</li>
<li>Opthea Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opt#NASDAQ">OPT</a>) shares fell 7.9% to $2.44 in pre-market trading.</li>
<li>HWH International Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hwh#NASDAQ">HWH</a>) shares declined 7.3% to $1.78 in pre-market trading after gaining more than 23% on Tuesday.</li>
<li>FaZe Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/faze#NASDAQ">FAZE</a>) shares declined 6.9% to $0.2978 in pre-market trading. FaZe Holdings shares jumped 107% on Tuesday after the company announced Rollbit will sponsor its Counter-Strike team.</li>
<li>Texas Instruments Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/txn#NASDAQ">TXN</a>) shares dipped 3.7% to $167.88 in pre-market trading after the company reported fourth-quarter financial results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36752351/netflix-tesla-and-3-stocks-to-watch-heading-into-wednesday"> Netflix, Tesla And 3 Stocks To Watch Heading Into Wednesday</a>

Pre-Market Outlook

CVKD

ENSC

ETAO

EVAX

FAZE

GETR

GREE

MMAT

NFLX

NYXH

RDHL

SNOA

VSME

ZCAR

Why Netflix Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) stock rose 39.6% to $18.73 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock moved upwards by 24.51% to $1.11. The company's market cap stands at $21.8 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock increased by 17.33% to $0.44. The market value of their outstanding shares is at $2.4 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares moved upwards by 14.76% to $0.65. The company's market cap stands at $4.0 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares moved upwards by 13.97% to $1.06. The market value of their outstanding shares is at $50.8 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares increased by 12.42% to $0.26. The market value of their outstanding shares is at $6.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock decreased by 16.5% to $2.02 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.7 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares decreased by 6.84% to $8.72. The company's market cap stands at $17.7 million. </li>
<li>Pluri (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUR#NASDAQ">PLUR</a>) shares fell 6.79% to $0.62. The market value of their outstanding shares is at $25.5 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock declined by 6.44% to $0.16. The company's market cap stands at $2.1 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) stock decreased by 6.1% to $0.26. The company's market cap stands at $56.7 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) stock declined by 5.77% to $0.26. The company's market cap stands at $7.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

BIVI

CELU

CNSP

GOVX

KURA

PLUR

SBFM

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock moved upwards by 28.1% to $1.46 during Tuesday's pre-market session. The company's market cap stands at $4.5 million. </li>
<li>Outlook Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) shares moved upwards by 23.52% to $0.42. The market value of their outstanding shares is at $109.3 million. </li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares moved upwards by 23.3% to $1.27. The company's market cap stands at $3.1 million. </li>
<li>Kronos Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>) shares increased by 18.69% to $1.27. The company's market cap stands at $74.0 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares moved upwards by 16.2% to $11.2. The market value of their outstanding shares is at $22.8 million. </li>
<li>Pluri (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUR#NASDAQ">PLUR</a>) stock increased by 11.03% to $0.63. The company's market cap stands at $26.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares decreased by 20.5% to $0.55 during Tuesday's pre-market session. The company's market cap stands at $150.1 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares decreased by 17.56% to $1.08. The market value of their outstanding shares is at $5.9 million. </li>
<li>Panbela Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBLA#NASDAQ">PBLA</a>) shares declined by 17.06% to $3.6. The market value of their outstanding shares is at $1.7 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock declined by 11.88% to $2.3. The company's market cap stands at $1.9 million. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) shares declined by 11.84% to $0.26. The company's market cap stands at $13.2 million. </li>
<li>Aravive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAV#NASDAQ">ARAV</a>) stock fell 11.76% to $0.04. The market value of their outstanding shares is at $3.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

ARAV

INVO

KRON

OTLK

PBLA

RNLX

VERO

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
<a href="https://investorplace.com/industries/healthcare/">Healthcare stocks</a> have started the year off very strongly, propelled by excitement about weight loss drugs and investments by Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>). The sector is also getting a lift from the U.S. Federal Reserve&rsquo;s decision to stop raising rates and its suggestions that it will cut rates later this year. Lower rates make it much easier for drug makers to obtain funds to finance the development of pharmaceuticals. Meanwhile, many pharmaceutical firms have rather low valuations because they dropped sharply in 2022 and much of 2023 due to overdone fears about the impact of rate hikes on the sector. For long-term investors who want to exploit the opportunities created by these trends, here are the three top healthcare stocks to buy on weakness.



<h2>vTv Therapeutics (VTVT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/lab-300x169.jpg" alt="Scientists in a lab"><div>Source: Matej Kastelic / Shutterstock</div></div>vTv therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtvt-stock-quote/">VTVT</a>) <a href="https://vtvtherapeutics.com/pipeline/ttp399/">has developed </a>TTP399, a drug candidate which reduces hypoglycemic episodes among Type 1 diabetes patients. Its use saw a reduction of 40% in a Phase 1 study. Those impressive results led the U.S. Food and Drug Administration to grant the drug &ldquo;breakthrough&rdquo; status in 2021. 



Since then, the firm has struggled to get a Phase 3 study of the drug off the ground. But that seems set to change, as VTVT <a href="https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-51-million-private-placement">announced on</a> Feb. 28 that it had obtained $51 million through a private placement from a number of institutional investors, including Samsara BioCapital and the&nbsp;JDRF T1D Fund. The fact that those two very prestigious enterprises would invest in vTv bodes well for the firm&rsquo;s flagship drug and for vTVT stock. 



Moreover, vTv reported that the proceeds will fully fund the Phase 3 trial of TTP399. Consequently, I&rsquo;m confident that the company will at long last get the Phase 3 trial of this extremely promising drug off the ground. vTv stated that it intends to launch the trial this year.



VTVT stock<a href="https://finance.yahoo.com/quote/VTVT?.tsrc=fin-srch"> jumped 98%</a> in the five days that ended on March 1, but it has sunk 49% in the last year and 88% since February 2020. Yet, the promising outlook of vTv&rsquo;s drug makes it one of the top healthcare stocks to buy.



<h2>Exact Sciences (EXAS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/exas-1600-300x169.png" alt="EXACT Sciences Corporation office exterior. EXAS stock."><div>Source: Tada Images / Shutterstock</div></div>Exact Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/exas-stock-quote/">EXAS</a>) develops cancer diagnostic tools. On Feb. 21, the firm reported <a href="https://seekingalpha.com/news/4069868-exact-sciences-gaap-eps-of-0_27-beats-0_21-revenue-of-647m-beats-7_3m">strong fourth-quarter results</a> as its top line jumped 17% year-over-year to $647 million. Meanwhile, its cash from operations <a href="https://seekingalpha.com/symbol/EXAS/cash-flow-statement">came in at</a> $69.5 million, up from $52 million in Q4 of 2022.



Also noteworthy is that the firm is well-positioned to rapidly grow its revenue from products other than its flagship Cologuard colon cancer test. The overseas revenue of Exact&rsquo;s Oncoptype tests, which measure the likelihood of breast cancer and colon cancer recurring, <a href="https://seekingalpha.com/article/4672209-exact-sciences-corporation-exas-q4-2023-earnings-call-transcript">climbed 48% last quarter</a> compared with Q4 of 2022. Meanwhile, Exact expects the annual sales of its Precision Oncology business, of which Oncotype is a part, to climb to $1 billion from its annual run rate last quarter of about $640 million. 



In order to accomplish that goal, the company plans to launch its Oncotype tests in new overseas markets while continuing to expand in its current markets, such as Japan, Germany and Italy. Exact also expects the sales generated by its OncoExTra cancer therapy selection test, which it launched in February 2023, to climb. 



Moreover, Exact intends to launch MRD tests, <a href="https://www.healthline.com/health/minimal-residual-disease#:~:text=MRD%20is%20a%20measure%20used,if%20further%20treatment%20is%20needed.">which shows whether </a>very few blood cancer cells are still present, along with Riskguard and OncoLiquid, which test individuals&rsquo; genes to determine how likely they are to contract certain cancers. 



EXAS has fallen 11% in the last three months and 20% so far this year. 



<h2>Excientia (EXAI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/research-lab-1600-300x169.jpg" alt="Scientist using a microscope"><div>Source: Maksim Shmeljov / Shutterstock.com</div></div>Nvidia&rsquo;s <a href="https://investorplace.com/2024/02/nvidia-is-betting-on-soundhound-ai-soun-stock/">decision to hike its stake in</a> Recursion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/rxrx-stock-quote/">RXRX</a>) last quarter to $76 million from $50 million bodes well for the outlook of Exscientia (NASDAQ:<a href="https://investorplace.com/stock-quotes/exas-stock-quote/">EXAS</a>). That&rsquo;s because both firms use AI to accelerate the drug discovery process and make it more effective. If Nvidia, which can use significant parts of its huge cash hoard to research other firms, is upbeat on the use of AI to research drugs, I&rsquo;m sure that it&rsquo;s an extremely promising sector. 



Additionally, Exscientia is already partnering with multiple, huge drugmakers. As a result of these alliances, I&rsquo;m confident in the effectiveness of its technology. 



EXAI stock has come under pressure in recent weeks because the company<a href="https://finance.yahoo.com/news/exscientia-fires-ceo-probe-over-135203281.html"> fired its</a> CEO Andrew Hopkins due to inappropriate relationships. The firm&rsquo;s Chief Science Officer, Dave Hallett, who presumably has more knowledge about its products and technology than Hopkins did, was chosen to become its interim CEO. Hallett can lean on other executives to help him make decisions about the business side of the company.



EXAI dropped 13% between Feb. 12 and March 1.



On the date of publication, Larry Ramer held long positions in VTVT and EXAS. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel&rsquo;s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been SMCI, INTC, and MGM. You can reach him on Stocktwits at @larryramer.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT793994">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793989">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793998">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/the-top-3-healthcare-stocks-to-buy-on-weakness-in-2024/">The Top 3 Healthcare Stocks to Buy on Weakness in 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The Top 3 Healthcare Stocks to Buy on Weakness in 2024

vTv Therapeutics (VTVT) just unveiled an update. vTv Therapeutics, Inc. recently updated their investor presentation and shared it on their website...

vTv Therapeutics Enhances Investor Communication with Update

vTv Therapeutics (VTVT) has provided an announcement. Anne Phillips has joined vTv Therapeutics, Inc. as a new independent director and will also l...

vTv Therapeutics Appoints Anne Phillips, Reshuffles Board Committees

vTv Therapeutics Inc (VTVT) stock is lower by -45.14% over the last 12 months. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives VTVT stock a score of  27 out of a possible 100. That rank is  influenced by a short-term technical score of 16. VTVT's rank also includes a long-term technical score of 66.  VTVT has an Over

vTv Therapeutics Inc (VTVT) Stock  Gains 16.69% This Week: Is It a Good Pick?

vTv Therapeutics Inc (VTVT) stock has risen 48.38% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. vTv Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on VTVT!See Full VTVT ReportWhat is Stock Sentiment?In investing

Should You Buy vTv Therapeutics Inc (VTVT) Stock on Wednesday?

The 50 rating InvestorsObserver gives to vTv Therapeutics Inc (VTVT)  stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 51 percent of stocks in the Biotechnology industry, VTVT's 50 overall rating means the stock scores better than 50 percent of all stocks. VTVT has an Overall

Where Does vTv Therapeutics Inc (VTVT) Stock Fall in the Biotechnology Field After It Has Risen 80.65% This Week?

Viking Therapeutics gains on early data for oral weight loss therapy

vTv Therapeutics files $250M mixed securities shelf

AMGN

BHVN

EXAI

EXAS

GPCR

NVDA

RYTM

TERN

VKTX

Press Releases

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Management

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT